Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population

INTRODUCTION: To evaluate the economic burden and treatment patterns of patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab, a C5 inhibitor, who were defined as blood transfusion-dependent (TD) versus blood transfusion-free (TF) in the US population. METHODS: Patients age...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Wendy Y., Sarda, Sujata P., Mody-Patel, Nikita, Krishnan, Sangeeta, Yenikomshian, Mihran, Mahendran, Malena, Lejeune, Dominique, Yu, Louise H., Duh, Mei Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342328/
https://www.ncbi.nlm.nih.gov/pubmed/34275086
http://dx.doi.org/10.1007/s12325-021-01825-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342328/
https://www.ncbi.nlm.nih.gov/pubmed/34275086
http://dx.doi.org/10.1007/s12325-021-01825-4

Ejemplares similares